Emmanuel Chautard

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8452519/publications.pdf

Version: 2024-02-01

28	669	567281 15	580821 25
papers	citations	h-index	g-index

30	30	30	1291
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	L1 chimeric transcripts are expressed in healthy brain and their deregulation in glioma follows that of their host locus. Human Molecular Genetics, 2022, 31, 2606-2622.	2.9	7
2	The Long Non-Coding RNA HOXA-AS2 Promotes Proliferation of Glioma Stem Cells and Modulates Their Inflammation Pathway Mainly through Post-Transcriptional Regulation. International Journal of Molecular Sciences, 2022, 23, 4743.	4.1	6
3	Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma. Radiotherapy and Oncology, 2021, 154, 227-234.	0.6	18
4	Relevance of the combination of external beam radiotherapy with the hypoxia-activated prodrug ICF05016 in an experimental model of extraskeletal myxoid chondrosarcoma. Investigational New Drugs, 2021, 39, 295-303.	2.6	0
5	Widespread overexpression from the four DNA hypermethylated HOX clusters in aggressive (IDHwt) glioma is associated with H3K27me3 depletion and alternative promoter usage. Molecular Oncology, 2021, 15, 1995-2010.	4.6	15
6	Interest and Limits of [18F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy. Frontiers in Oncology, 2021, 11, 789769.	2.8	3
7	[18F]ML-10 PET imaging fails to assess early response to neoadjuvant chemotherapy in a preclinical model of triple negative breast cancer. EJNMMI Research, 2020, 10, 2.	2.5	6
8	Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models. Frontiers in Oncology, 2019, 9, 549.	2.8	11
9	Altering DNA Repair to Improve Radiation Therapy: Specific and Multiple Pathway Targeting. Frontiers in Oncology, 2019, 9, 1009.	2.8	84
10	Transcriptional alterations in glioma result primarily from DNA methylationâ€“independent mechanisms. Genome Research, 2019, 29, 1605-1621.	5.5	35
11	WNT6 is a novel oncogenic prognostic biomarker in human glioblastoma. Theranostics, 2018, 8, 4805-4823.	10.0	35
12	Second course of stereotactic radiosurgery for locally recurrent brain metastases: Safety and efficacy. PLoS ONE, 2018, 13, e0195608.	2.5	40
13	Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis. Journal of Neuro-Oncology, 2017, 135, 381-390.	2.9	21
14	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. Molecular Neurobiology, 2017, 54, 5780-5797.	4.0	52
15	Predictive biomarkers of resistance to hypofractionated radiotherapy in high grade glioma. Radiation Oncology, 2017, 12, 123.	2.7	13
16	Global Conservation of Protein Status between Cell Lines and Xenografts. Translational Oncology, 2016, 9, 313-321.	3.7	12
17	Different dose rate-dependent responses of human melanoma cells and fibroblasts to low dose fast neutrons. International Journal of Radiation Biology, 2016, 92, 527-535.	1.8	7
18	Fractionated stereotactic radiotherapy of benign skull-base tumors: a dosimetric comparison of volumetric modulated arc therapy with RapidarcÂ® versus non-coplanar dynamic arcs. Radiation Oncology, 2016, 11, 58.	2.7	6

#	Article	IF	Citations
19	The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patientsâ€™ survival. Carcinogenesis, 2016, 37, 169-176.	2.8	14
20	<scp>STAT3</scp> Serine 727 Phosphorylation: A Relevant Target to Radiosensitize Human Glioblastoma. Brain Pathology, 2016, 26, 18-30.	4.1	24
21	Highly efficient radiosensitization of human glioblastoma and lung cancer cells by a G-quadruplex DNA binding compound. Scientific Reports, 2015, 5, 16255.	3.3	25
22	A Preclinical Study Combining the DNA Repair Inhibitor Dbait with Radiotherapy for the Treatment of Melanoma. Neoplasia, 2014, 16, 835-844.	5.3	40
23	Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness. Journal of Neuro-Oncology, 2014, 117, 205-215.	2.9	48
24	New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathway. Analytical and Bioanalytical Chemistry, 2014, 406, 3743-3754.	3.7	19
25	Telomere Targeting with a New G4 Ligand Enhances Radiation-Induced Killing of Human Glioblastoma Cells. Molecular Cancer Therapeutics, 2011, 10, 1784-1795.	4.1	33
26	Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro-Oncology, 2010, 12, 434-43.	1.2	58
27	Increased expression of the oncogenic KLF6-SV1 transcript in human glioblastoma. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1167-1170.	2.3	12
28	Strong correlation between VEGF and MCL-1 mRNA expression levels in B-cell chronic lymphocytic leukemia. Leukemia Research, 2009, 33, 1623-1626.	0.8	16